Patent 8993746 was granted and assigned to Alnylam Pharmaceuticals on March, 2015 by the United States Patent and Trademark Office.
This invention relates to modified double-stranded oligoribonucleic acid (dsRNA) having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene.